Abstract:Abstract INTRODUCTION Intestinal fibrosis is a serious complication of Crohn's disease (CD) and is caused by the excess deposition of extracellular matrix (ECM) proteins. Numerous cell types, including intestinal epithelial and mesenchymal cells, are implicated in this but research efforts are impaired by a lack of in vitro models. To overcome this, we have previously developed a human model of intestinal fibrosis using iPSC-derived epithelial and mesenchymal cells generated from both control and CD patients. Using this model, we aimed to further characterize the transcriptomic signature associated with the fibrotic response as well as other functional hallmarks of fibrosis. METHODS iPSCs from 19 CD patients with (10) and without (9) fibrotic complications were directed to form HIOs. As iPSC-derived HIOs contain epithelial and mesenchymal cells, the organoids were dissociated to generate purified cultures of epithelial only-HIOs (eHIOs) and intestinal mesenchymal cells (MSCs). eHIO and MSC cultures were treated with TNFα and TGFβ, alone or in combination. We evaluated the transcriptomic profile of both cell types via RNA-seq and carried out additional studies via ELISA, ECM staining and scratch assay. RESULTS RNAseq analysis on the effects of cytokine induction in eHIOs lead to an enrichment in pathways associated with inflammation and regulation of the immune response. Furthermore, eHIOs from patients with fibrotic complications showed a significant upregulation of ORM1 regardless of culture conditions, which was subsequently confirmed at the protein level indicating an intrinsic difference between both patient groups. RNAseq analysis on MSC cultures found differentially expressed genes clustered in pathways associated with ECM production and remodeling, and cell migration and proliferation. Cell migration capacity of MSCs was assessed by measuring the reduction in scratch area and under basal conditions, MSCs from the fibrotic cohort had a lower rate of cell migration (40.81%) compared to the non-fibrotic cohort (20.97%); notably, the addition of TNFα appeared to accelerate the migration capacity of MSCs in both fibrotic (14.54%) and non-fibrotic (6.56%) samples. Finally, compared to untreated cultures, MSCs treated with TNFα/TGFβ exhibited a significant increase in ECM deposition (2.64- and 2.29-fold increase for non-fibrotic and fibrotic, respectively). CONCLUSION We have demonstrated the functionality of our model of intestinal fibrosis generated from iPSC-derived epithelial and mesenchymal cells from CD patients. Furthermore, we have identified both generalized and intrinsic differences in our cohort of patients with fibrotic complications. Future experiments on the role of ORM1 in intestinal fibrosis and its effects on mesenchymal cells could provide a deeper understanding of the events leading the development of intestinal fibrosis in CD patients.

DOP32 Crohn’s Disease Stricture Matrisome Analysis Reveals the Anti-Fibrotic Activity of Milk-Fat Globule-Epidermal Growth Factor 8 (MFGE8)

Milk fat globule-epidermal growth factor 8 (MFGE8) prevents intestinal fibrosis

DOP33 Single-cell analysis identifies pathological fibroblasts as a new therapeutic target to prevent intestinal fibrosis in Crohn’s disease

Interleukin 36 receptor-inducible matrix metalloproteinase 13 mediates intestinal fibrosis

Inhibition of GDNF-Driven Macrophage-to-Myofibroblast Transition Protects Against Colitis-Associated Intestinal Fibrosis

DOP61 Up-regulated Gremlin 1 in fibroblasts from Crohn’s Disease fibrotic strictures: A potential therapeutic target

Milk Fat Globule Egf-8 Attenuates Intestinal Inflammation In Murine Experimental Colitis Via Inhibition Of Nf-Kappa B Activation

Creeping Fat-Derived Free Fatty Acids Induce Hyperplasia Of Intestinal Muscularis Propria Muscle Cells – A Novel Link Between Fat And Intestinal Stricture Formation In Crohn'S Disease

Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn’s disease

Molecular basis of intestinal fibrosis in inflammatory bowel disease

A MODEL TO STUDY INTESTINAL FIBROSIS IN IPSC-DERIVED HUMAN EPITHELIAL AND MESENCHYMAL CELLS FROM CROHN’S DISEASE PATIENTS

DOP88 Lipids drive myofibroblast activation and the epithelial-mesenchymal transition process in Crohn’s Disease

Epigenetic and Metabolic Reprogramming of Fibroblasts in Crohn's Disease Strictures Reveals Histone Deacetylases as Therapeutic Targets

Epigenetic and Metabolic Reprogramming of Fibroblasts in Crohn’s Disease Strictures Reveals Histone Deacetylases as Therapeutic Targets

Sa1797 Cell Cycle Arrest, DNA Damage and Remodeling of the Colonic Epithelial Barrier Composition and Function Underlies DSS-Induced Colitis

Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease

Matrix metalloproteinases in intestinal fibrosis

Human Intestinal Myofibroblasts Deposited Collagen VI Enhances Adhesiveness for T Cells – A Novel Mechanism for Maintenance of Intestinal Inflammation

Targeting Twist1 to Inhibit FAP Plus Fibroblasts in the Prevention of Intestinal Fibrosis in Crohn's Disease

TWIST1+FAP+ Fibroblasts in the Pathogenesis of Intestinal Fibrosis in Crohn’s Disease

P003 Metabolic Reprogramming in Intestinal Fibrosis: Integrating Metabolomics, Single-Cell Transcriptomics and Isotope Tracing